Bazlitoran sodium
Based on 1 Customer Validation
Bazlitoran sodium (IMO-8400 sodium) is an oligonucleotide-based TLR7/8/9 antagonist. Bazlitoran sodium blocks the activation of Toll-like receptors 7, 8, and 9. Bazlitoran sodium inhibits cytokine responses mediated by Toll-like receptors 7, 8, and 9. Bazlitoran sodium is associated with injection site reactions. Bazlitoran sodium improves moderate-to-severe plaque psoriasis.
Para uso exclusivo en investigación. No vendemos a pacientes.
- Pureza: 95.30%
- No. CAS: 1613607-40-1
- Fòrmula: C179H225N52Na17O101P17S17
- Peso molecular:6183.47
-
Almacenamiento:
-20°C, sealed storage, away from moisture
* In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Actividad biológica
-
Chemical Information
- Pureza y Documentación
- Referencias
-
Help & FAQs
Actividad biológica
|
TLR7 |
TLR8 |
TLR9 |
Bazlitoran sodium inhibits toll-like receptor 7, 8, and 9-mediated cytokine responses in cell-based assays[2].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
Chemical Information
-
No. CAS 1613607-40-1
-
Appearance Solid
-
Peso molecular 6183.47
-
Fòrmula C179H225N52Na17O101P17S17
-
Color White to off-white
-
SMILES
[Bazlitoran (sodium)]
-
Synonyms
IMO-8400 sodium
-
Envío
Room temperature in continental US; may vary elsewhere.
-
Almacenamiento
-20°C, sealed storage, away from moisture
* In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)
Pureza y Documentación
-
Ficha de datos (266 KB)
-
SDS (252 KB)
- English - EN (252 KB)
- Français - FR (252 KB)
- Deutsch - DE (252 KB)
- Norwegian - NO (252 KB)
- Español - ES (252 KB)
- Swedish - SV (252 KB)
- Italian - IT (252 KB)
- Korean - KR (252 KB)
- Portuguese - PT (252 KB)
-
Instrucciones de manejo (2242 KB)
Referencias
[1]. Kim YJ, Schiopu E, Dankó K, et al. A phase 2, double-blinded, placebo-controlled trial of toll-like receptor 7/8/9 antagonist, IMO-8400, in dermatomyositis. J Am Acad Dermatol. 2021;84(4):1160-1162. [Content Brief]
[2]. Balak DM, van Doorn MB, Arbeit RD, et al. IMO-8400, a toll-like receptor 7, 8, and 9 antagonist, demonstrates clinical activity in a phase 2a, randomized, placebo-controlled trial in patients with moderate-to-severe plaque psoriasis. Clin Immunol. 2017;174:63-72. [Content Brief]
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
Bazlitoran sodium Related Classifications
HY-177617A Related Classifications
Powered by Bioz